Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model

As the pharmaceutical industry wrestles with the prospect of U.S. tariffs and global retaliation that could cut into future profits, the changing dynamic has industry leaders considering capital allocation strategies that could shift priorities in a meaningful way.